MSC
[용어속성] Gene
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies
Editorial
[키워드] agency
antiviral drug
blueprint
cause
caused
Cell
cellular
circulating
clinical
clinical trial
Combination
combinations
Community
Consensus
COVID-19
COVID-19 mortality
death
death rate
disease
effective
HDTs
Host
host-directed therapy
immune
Inflammatory response
initiated
long-term functional disability
MERS-CoV
morbidity
Mortality
mortality rates
MSC
MSC therapy
MSCs
novel coronavirus disease
ongoing trial
pandemic
pathogen
pathogenesis of SARS-CoV-2
Patient
reducing mortality
regimen
registry
reported
Repurposed drug
severe COVID-19 disease
specific treatment
STEM
the WHO
therapeutic interventions
therapy
Treatment
treatment trial
Trial
turn
underlie
Vaccine
WHO
WHO ICTRP
World Health Organization
[DOI] 10.1016/j.ijid.2020.05.040 [Article Type] Editorial
[DOI] 10.1016/j.ijid.2020.05.040 [Article Type] Editorial
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence—FAST Evidence
Review article
[키워드] accelerated
acute respiratory distress syndrome
Admission
Analysis
anticipated
appear
approval
ARDSacute respiratory distress syndrome
candidate
Cell
cells
cellular
cellular therapy
clinical
clinical trial
clinically
complex
conducted
COVID-19
Critical
cumulative
detect
determine
effective
Effectiveness
enrolment
framework
heterogeneity
ICUIntensive Care Unit
identify
implementation
intensive care
intensive care unit
Intervention
mechanical ventilation
Mesenchymal stromal cell
Meta-analysis
Mortality
MSC
MSCmesenchymal stromal cell
multiple study
natural killer
NK cells
NKnatural killer
outcome
outcomes
Patient
predominant
Prevent
receive
reductions in
Registered
registry
Regulatory
review
Safe
Sample size
searched
similar study
stromal cell
Study design
subject
subset
Support
synthesis
therapy
treat
treatments for COVID-19
Trial
while
WHO
[DOI] 10.1016/j.tmrv.2020.06.001 [Article Type] Review article
[DOI] 10.1016/j.tmrv.2020.06.001 [Article Type] Review article
Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease
Editorial
[키워드] acute respiratory illness
Adipocyte secreted exosomal microRNA
adipose derived stem cells
administration
affected
autologous
caused
coronavirus
coronavirus disease
COVID-19
effective
Efficacy
endogenous repair
immune system
Infection
infiltration
inhibit
intravenous
lung
Mesenchymal stem cells
microenvironment
MSC
MSCs
MSCs therapy
outcome
Patient
Pneumonia
Potential
reported
respiratory activity
Safe
SARS-CoV-2
STEM
stem cell
the SARS-CoV-2
therapy
these cell
treated
treatment for COVID-19
[DOI] 10.14336/AD.2020.0422 PMC 바로가기 [Article Type] Editorial
[DOI] 10.14336/AD.2020.0422 PMC 바로가기 [Article Type] Editorial
Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
Review
[키워드] acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
Affect
anti-inflammatory macrophages
ARDS
B cells
clinical study
clinical trial
coronavirus
coronavirus disease
country
COVID-19
Cytokine storm
dendritic cells
Effect
Exosome
Exosomes
health condition
healthcare
Immune cell
induce
initiated
mechanism
mesenchymal stem cell
Mesenchymal stem cells
MSC
MSCs
multiple organ failure
Novel coronavirus
novel coronavirus disease
Registered
Regulatory
resolved
SARS-CoV-2
SARS-COV-2 infection
Severe case
Spread
stem cell
syndrome
T cells
therapy
Treatment
Trial
trials
virus
worldwide pandemic
[DOI] 10.1186/s41232-020-00121-y PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s41232-020-00121-y PMC 바로가기 [Article Type] Review
Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection
Article
[키워드] Activation
adaptive
affecting
Autoimmune
Autoimmunity
being
binding
Cell
cell membrane
Characteristics
clinical setting
clinical study
component
COVID-19
Critical
Cytokine storm
Cytokines
cytosolic
disorder
effective
EVs
exceptional
Exosome
Exosomes
Extensive
Extracellular
extracellular vesicle
Extracellular vesicles
Factor
function
Growth factors
immune
immune cells
Immunological disorders
immunomodulator
Inflammation
inflammatory disease
Inflammatory response
inhibiting
Intercellular communication
investigated
lower risk
Lung pathology
membrane
mesenchymal stem cell
Mesenchymal stem cells
Microvesicles
Migration
miRNA
Mortality
mRNA
MSC
MSCs
outcome
pandemic
paracrine
parent cells
pathway
proliferation
regenerative
regulate
rejection
Research
SARS-CoV-2
SARS-COV-2 infection
secreted
secretion
target cell
tested
therapeutic agent
Therapies
therapy
tolerogenic immune response
transcription factors
Treatment
triggered
unique
variety
[DOI] 10.3906/biy-2002-79 PMC 바로가기 [Article Type] Article
[DOI] 10.3906/biy-2002-79 PMC 바로가기 [Article Type] Article
Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19
Clinical Trial
[키워드] absolute neutrophil count
acute phase reactant
acute respiratory distress
administration
adverse event
Allogeneic
ARDS
average
bone
Bone marrow
C-reactive protein
CD3
CD4
CD8
clinical status
cohort study
COVID-19
criteria
Critically ill
Cytokine storm
D-dimer
declined
determine
downregulate
Efficacy
evaluated
Exosome
expired
ferritin
fraction
Future
Immunity
improvement
intravenous dose
Lymphocyte count
lymphopenia
Marrow
MSC
nonrandomized
Open-label
oxygen
Oxygenation
p value
PaO
Patient
polymerase chain
provided
Randomized controlled trial
RCTs
reduction
remained
safety endpoint
safety profile
SARS-CoV-2
severe COVID-19
single hospital
STEM
stem cell
survival rate
syndrome
therapeutic
therapeutic potential
Treatment
[DOI] 10.1089/scd.2020.0080 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1089/scd.2020.0080 PMC 바로가기 [Article Type] Clinical Trial
Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID ‐19
Concise Review
[키워드] accompanied
accumulated
acute respiratory distress
Allogeneic
ARDS
Asthma
Bacterial
bacterial pneumonia
chronic obstructive
clinical trial
Clinical use
COPD
COVID
COVID‐19
COVID‐19
curative
current
Cytokine storm
disease
Diseases
disorder
disorders
Effect
effective
Evidence
Gleaning
Idiopathic pulmonary fibrosis
immunomodulatory property
Influenza
lack
lung
lung disorders
mesenchymal stem cell
Mesenchymal stem cells
mortality rate
MSC
MSC therapy
MSCs
novel coronavirus disease
outcomes
pandemic
Perspective
preclinical data
pulmonary conditions
pulmonary disease
pulmonary injury
regenerative
reported
stem cell
Stem cell therapy
syndrome
therapeutic
therapeutic use
therapy
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review
Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics
급성호흡곤란증후군의 간엽줄기세포치료제: 기초부터 임상까지
Review
[키워드] 2019 novel coronavirus
2019 novel coronavirus disease
acute respiratory distress
acute respiratory distress syndrome
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
alveolar fluid clearance
anti-apoptotic
Anti-inflammatory
approaches
ARDS
Bacterial
breath
caused
Cell
cell damage
Cell therapy
China
clinical study
clinics
coronavirus
coronavirus disease
COVID-19
COVID-19 patient
develop
disease
disrupt
distal
Effects
Efficacy
ENhance
epithelial
epithelial cell
event
Extracellular vesicles
Factor
high mortality
intrinsic
limit
lung
mechanism
mesenchymal stem cell
Mesenchymal stem cells
morbidity
MSC
MSC therapy
multiple organ failure
Novel coronavirus
novel coronavirus disease
occurred
optimization
Organ failure
organ injury
paracrine
pathophysiological
patients with ARDS
Pneumonia
promote
pulmonary endothelial
respiratory
respiratory distress
SARS-CoV-2
SARS-CoV-2-infected patient
SARS-CoV-2-infected patients
severe acute respiratory syndrome Coronavirus
severe pneumonia
stem cell
supportive care
survival
syndrome
therapeutic
therapy
variety
[DOI] 10.1007/s13238-020-00738-2 PMC 바로가기 [Article Type] Review
[DOI] 10.1007/s13238-020-00738-2 PMC 바로가기 [Article Type] Review
Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial
Letter
[키워드] 1:1
active malignancy
acute respiratory distress syndrome
Administered
administration
age
approval
approved
ARDS
assessment
automated
Berlin
blinded
Cell
cell suspension
cellular
changes in
chronic liver disease
class
clinical
Clinical diagnosis
Clinical outcome
clinical outcomes
clinical trial
comparator
Compliance
conducted
control group
Controlled trial
COVID 19
COVID-19
COVID-19 pandemic
declined
defined
described
determine
diagnosis of COVID-19
dissemination
Donor
Dose escalation
driving
Effect
Efficacy
element
eligible
Elizabeth
enrolled
ethics committee
EudraCT
excluded
facilitate
failure
fixed dose
hospital
ICU
incidence
Inclusion
increase in
index
individual
information
infusion
intensive care unit
Intervention
Invasive mechanical ventilation
investigator
King’s College London
London
Mesenchymal stem cells
Mesenchymal stromal cells
MHRA
moderate
Mortality
MSC
MSCs
NIHR
number
objective
open label
Other
outcome
pandemic
PaO
participant
Patient
patient population
patients with ARDS
PCR test
PF ratio
Phase 1
Phase 2
Placebo
placebo-controlled
protocol
protocol amendment
Public
randomised
randomised controlled trial
REC
receiving
recruited
recruitment
repair
reported
Research
respiratory
Resuscitation
Sample size
secondary
Secondary objective
Secondary outcomes
Serious Adverse Events
severe ARDS
single intravenous infusion
SOFA
solution
Standard
steering committee
stratified
stromal cell
Study protocol
Therapeutics
therapy
trauma
Treatment
Trial
triple blinded
Trust
umbilical
United Kingdom
university
Venous Thromboembolism
Ventilation
verbal
Volume
web-based randomisation system
website
WHO
Withdrawal
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04416-w PMC 바로가기 [Article Type] Letter